ALZ-801

an orally available, valine-conjugated prodrug of tramiprosate

Also Known As:

1-propanesulfonic acid, 3-((2-amino-3-methyl-1-oxobutyl)amino)-; 3-(l-valyl) amino-1-propanesulfonic acid; 3-(valylamino)-1-propanesulfonic acid

Networked: 3 relevant articles (0 outcomes, 1 trials/studies)

1.	Edema (Dropsy) 12/01/2020 - "ALZ-801 selectively and fully inhibits the formation of Aβ42 oligomers at the clinical dose, without evidence of vasogenic edema, and will be evaluated in a phase 3 trial in homozygous APOE4/4 patients with early AD. "
2.	Alzheimer Disease (Alzheimer's Disease) 01/01/2018 - "ALZ-801 is an oral, small-molecule inhibitor of beta amyloid (Aβ) oligomer formation in clinical development for Alzheimer's disease (AD). " 01/01/2018 - "Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer's Disease."
3.	Amyloid Plaque 12/01/2020 - "Aducanumab and gantenerumab partially target oligomers, while mostly clearing insoluble amyloid plaques; BAN2401 preferentially targets soluble protofibrils (large oligomers) over plaques; and ALZ-801 blocks the formation of oligomers without binding to plaques. "